Ken Griffin Foghorn Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,900 shares of FHTX stock, worth $47,613. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,900
Previous 7,600
22.37%
Holding current value
$47,613
Previous $50,000
34.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding FHTX
# of Institutions
72Shares Held
32.7MCall Options Held
6KPut Options Held
1.8K-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$102 Million8.71% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$42.8 Million0.93% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.52MShares$20.3 Million0.3% of portfolio
-
Raymond James & Associates St Petersburg, FL2.3MShares$18.5 Million0.01% of portfolio
-
Euclidean Capital LLC New York, NY1.57MShares$12.7 Million1.14% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $336M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...